LEDGER
Portfolio
← All instruments

C2PU.SI

SGX50SES

Parkway Life Real Estate Investment Trust

Real Estate · REIT - Healthcare Facilities · Singapore

S$4.10
+0.49% today
Mkt Cap
S$2.68B
P/E
17.83×
Fwd P/E
22.07×
Div Yield
4.39%
Beta
0.34×
52W Range
35.8%
Company profileSource: provider

Parkway Life Real Estate Investment Trust is a unit trust constituted pursuant to the trust deed (as amended) (the Trust Deed) between Parkway Trust Management Limited (the Manager) and HSBC Institutional Trust Services (Singapore) Limited (the Trustee). On 12 July 2007, the Trust was declared as an authorized unit trust scheme under the Trustees Act, Chapter 337. The Trustee is under a duty to take into custody and hold the assets of the Trust and its subsidiaries (the Group) in trust for the holders (Unitholders) of units in the Trust. On 23 August 2007, the Trust was admitted to the Official List of the Singapore Exchange Securities Trading Limited and was included under the Central Provident Fund Investment Scheme on the same date. The principal activity of the Trust is to invest primarily in income-producing real estate and/or real estate-related assets in the Asia-Pacific region (including Singapore) that are used primarily for healthcare and/or healthcare-related purposes (including but not limited to, hospitals, healthcare facilities and real estate and/or real estate assets used in connection with healthcare research, education, and the manufacture or storage of drugs, medicine and other healthcare goods and devices), whether wholly or partially owned, and whether directly or indirectly held through the ownership of special purpose vehicles whose primary purpose is to own such real estate. Parkway Life Real Estate Investment Trust is domiciled in Singapore and was established on July 07, 2007.

www.plifereit.com
By the numbersComputed from live metrics

Shares trade at a moderate 17.8× trailing earnings, easing to 22.1× on forward estimates. Profitability shows a net margin of 103.3% and return on equity of 10.0%. Leverage is high at 5.0× net debt/EBITDA. Revenue grew -2.1% year-on-year. It yields 4.4% in dividends. The mean analyst target of SGD4.81 sits 17.4% above the current price (no rating, 6 analysts).

AI analysisAI-generated · 04 Jul 2026 · claude-opus (research)

business model

Parkway Life REIT is one of Asia's largest listed healthcare REITs, owning hospitals, nursing homes and aged-care facilities and leasing them on long tenancies with rent-escalation formulas. Its Singapore hospitals are leased to a Parkway/IHH operator, its large Japanese portfolio comprises nursing and care homes, and it has expanded into nursing homes in Europe (France). Long leases with downside-protected, often CPI-linked rent reviews give it highly visible income.

revenue segments

Revenue comes from three main geographies: Singapore hospitals (Mount Elizabeth, Gleneagles and Parkway East) under a long master lease with a minimum guaranteed rent step-up, a large portfolio of Japanese aged-care and nursing homes, and a newer European (French) nursing-home portfolio. Singapore and Japan have historically contributed the bulk of rental income.

key dependencies

It depends on the creditworthiness of its master lessees and operators (notably the Parkway/IHH hospital operator in Singapore and Japanese care operators), the rent-review formula tied to CPI and hospital revenue, and the yen/euro versus Singapore dollar. Japanese demographics and Singapore healthcare demand underpin occupancy.

competitors

It competes for healthcare assets and capital with First REIT (Indonesia-focused healthcare) and other yield-focused Singapore REITs, and with private healthcare-property investors and operators in Japan and Europe for acquisitions.

moat

Its moat is a very long weighted-average lease expiry, rent structures with guaranteed minimum increases and CPI linkage that protect income in downturns, and defensive exposure to non-cyclical healthcare real estate anchored by the IHH/Parkway relationship. Ageing populations in Japan and Singapore support long-term demand.

risks

Risks include concentration in a single Singapore hospital master lease, yen depreciation eroding Japanese income when translated to Singapore dollars, operator financial health, rising interest costs, and regulatory or reimbursement changes in healthcare across its markets.

01

Financials & metrics

as of 04 Jul 2026
52-week rangeMid-range · 36%
Low S$3.91Now S$4.10High S$4.44

Price is around the middle of its range. Green = nearer the yearly low, red = nearer the high — a position indicator, not a buy/sell signal.

Valuation
Profitability
Growth
Financial Health
Efficiency
Cash Flow
Per Share
Dividend
Market

Tap any metric for an explanation. provider computedN/A not available from source

Income-statement history isn't available for this security.

02

Dividends

This company does not currently pay a dividend.

03

Analyst assessment

as of 04 Jul 2026
6 analysts
Implied to mean target
+17.4%
Low S$4.11High S$5.45
Now
S$4.10
Low
S$4.11
Mean
S$4.81
High
S$5.45
Rating distribution
Strong Buy 1
Buy 4
Hold 1
Sell 0
Strong Sell 0

Aggregate consensus only. Named per-analyst targets require a premium source and are not shown; the data model is ready to hold them if one is added.

04

Technicals

as of 03 Jul 2026
CloseSMA 50SMA 200Death cross
SMA 50
S$4.00
SMA 200
S$4.05
RSI (14)
70.6
MACD
0.03
RSI (14) · overbought > 70 · oversold < 30
05

News